Ethris

Activities: Nutraceutical

Trending Articles

  1. NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant...
  2. Isopod Rapid Cleanrooms: the ideal elite controlled environment pod solution for Life Sciences and Engineering start-ups The Guardtech Group’s quick-assembly cleanroom pods combine superior performance, build quality and cost-effectiveness to give new applications the perfect platform to get...
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Delivering precision: why advanced therapies are redefining pharmaceutical logistics As advanced therapies narrow tolerances and personalise care, pharmaceutical logistics is being redefined as a precision-driven extension of treatment delivery, writes Michael...
  4. Nose-to-brain delivery outperforms systemic BBB technologies according to MetP Pharma The pioneering company has published preclinical data that strongly supports the advantages of its proprietary nose-to-brain drug delivery technology compared with systemic...
  5. AstraZeneca strengthens weight management pipeline with CSPC Pharmaceuticals collaboration The pair have signed a strategic collaboration covering eight obesity and type 2 diabetes programmes, including a clinical-ready GLP-1/GIP asset, AI-driven peptide discovery...

Upcoming event

High Shear = Mixing Success

19 February 2026 | Virtual See all

Related Content

Manufacturing

Evonik and Ethris partner to develop novel lipid nanoparticle platform for nucleic acid delivery

The partnership will enable Evonik to bring more stable and targeted nucleic acid therapies and vaccines to market
Manufacturing

Ethris and Thermo Fisher Scientific to provide mRNA technology to biopharma market

Ethris will combine its mRNA technology platforms with Thermo Fisher's GMP manufacturing capacity to serve the biopharmaceutical market
Manufacturing

Ethris and Lonza collaborate to develop spray-dried mRNA vaccines for respiratory disease prevention

Collaboration is part of Ethris’ strategy to develop spray-dried mucosal mRNA vaccines that are stable at room temperature and capable of generating a localised immune response, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), including a first candidate against influenza
Drug Delivery

Lonza and Ethris team up to develop mRNA vaccines for respiratory diseases

The two hope to produce a temperature-stable mRNA vaccine for influenza, which may promote mucosal immunity through its nasal delivery system
Research & Development

Ethris bags $5m to develop stable spray-dried RNA vaccines

The grant will support Ethris' R&D efforts, which are focused on developing room temperature-stable RNA vaccines suitable for mucosal delivery
Subscribe now